Stopping Ozempic may be bad for your health
In people with type 2 diabetes (T2D) and no established cardiovascular disease (CVD), starting glucagon-like peptide-1 receptor agonist (GLP-1) treatment and then stopping is associated with twice the combined risk of heart attack, stroke or death compared with staying on treatment, according to a study published in The Lancet Regional Health—Europe.
Read original article on Medical Xpress - latest medical and health news stories →Related news
-
EEG analysis estimates depressive symptom severity in adults not receiving psychiatric treatment
United Kingdom
-
Norovirus No. 1 cause of cruise ship outbreaks for past 30 years, but other pathogens gaining
United Kingdom
-
Resistance training key to maintaining muscle function during GLP-1 weight loss, study shows
United Kingdom
-
Uncovering the regulators of inflammatory responses in macrophages
United Kingdom
-
Almost one in four Americans believe misinformation about the cause of autism
United Kingdom
-
Night owls who eat late may face higher health risks
United Kingdom
-
Older female influencers challenging stereotypes around aging
United Kingdom
-
New stem cell models reveal how earliest human placenta structures take shape
United Kingdom